Regeneron Pharmaceuticals Stock Today
| REGN Stock | USD 723.47 10.22 1.43% |
PerformanceVery Weak
| Odds Of DistressLow
|
Regeneron Pharmaceuticals is selling at 723.47 as of the 25th of February 2025; that is 1.43 percent increase since the beginning of the trading day. The stock's open price was 713.25. Regeneron Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on February 13, 2025, Representative Julie Johnson of US Congress acquired under $15k worth of Regeneron Pharmaceuticals's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of April 1991 | Category Healthcare | Classification Health Care |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 107.51 M outstanding shares of which 2.19 M shares are at this time shorted by private and institutional investors with about 2.52 trading days to cover. More on Regeneron Pharmaceuticals
Moving against Regeneron Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Regeneron Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Marion McCourt | ||||
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Nasdaq 100, SP 500 Index, NASDAQ 100 Equal, Nasdaq 100 Total, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ 100 Pre, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Biotech, Health Management, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsRegeneron Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Regeneron Pharmaceuticals' financial leverage. It provides some insight into what part of Regeneron Pharmaceuticals' total assets is financed by creditors.
| |||||
Regeneron Pharmaceuticals (REGN) is traded on NASDAQ Exchange in USA. It is located in 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 and employs 15,106 people. Regeneron Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 79.09 B. Regeneron Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 107.51 M outstanding shares of which 2.19 M shares are at this time shorted by private and institutional investors with about 2.52 trading days to cover.
Regeneron Pharmaceuticals currently holds about 7.02 B in cash with 4.42 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 65.75.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRegeneron Pharmaceuticals owns a total of 107.51 Million outstanding shares. The majority of Regeneron Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regeneron Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regeneron Pharmaceuticals. Please pay attention to any change in the institutional holdings of Regeneron Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. On February 13, 2025, Representative Julie Johnson of US Congress acquired under $15k worth of Regeneron Pharmaceuticals's common stock.
Check Regeneron Ownership Details
Regeneron Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Loomis, Sayles & Company Lp | 2024-12-31 | 1.6 M | |
| Amundi | 2024-12-31 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.4 M | |
| Norges Bank | 2024-12-31 | 1.1 M | |
| Northern Trust Corp | 2024-12-31 | 1.1 M | |
| Ubs Asset Mgmt Americas Inc | 2024-12-31 | 982.1 K | |
| Bank Of America Corp | 2024-12-31 | 940.2 K | |
| International Assets Investment Management, Llc | 2024-09-30 | 880.9 K | |
| Amvescap Plc. | 2024-12-31 | 864.2 K | |
| Jpmorgan Chase & Co | 2024-09-30 | 15 M | |
| Vanguard Group Inc | 2024-12-31 | 9.3 M |
Regeneron Pharmaceuticals Historical Income Statement
Regeneron Stock Against Markets
Regeneron Pharmaceuticals Corporate Management
| Joseph JD | General VP | Profile | |
| Patrice Gilooly | Senior Operations | Profile | |
| Andrew Murphy | Executive Research | Profile | |
| Bob McCowan | Senior Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.21) | Earnings Share 38.34 | Revenue Per Share | Quarterly Revenue Growth 0.103 | Return On Assets |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.